Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Sees a 46.4% Decrease

Xenetic Biosciences Inc (NASDAQ:XBIO) has recently experienced a significant reduction in its short interest for the month of March. As of March 15th, the short interest stood at only 4,500 shares, marking a steep decline of 46.4% from the total of 8,400 shares reported on February 28th. This reduction indicates that approximately 0.4% of the company's shares are currently being sold short. Given the average trading volume of 7,100 shares, the short-interest ratio is calculated to be 0.6 days.

Current Stock Performance of Xenetic Biosciences

On Friday, shares of XBIO opened at a price of $3.30. The company has a market capitalization of $5.08 million, with a price-to-earnings ratio of -1.24 and a beta of 2.17. The fifty-day simple moving average for the company is $3.91, while the two-hundred-day simple moving average is $3.98. Over the past year, Xenetic Biosciences has recorded a low of $2.78 and a high of $5.20.

In their latest quarterly earnings report released on March 18th, the company reported an earnings per share (EPS) of ($0.68), which was lower than analyst expectations of ($0.20) by ($0.48). In terms of revenue, Xenetic Biosciences generated $0.65 million, surpassing the consensus estimate of $0.18 million. The company recorded a negative net margin of 161.63% along with a negative return on equity of 49.51%. Analysts forecast that the company will achieve an EPS of -1.01 for the current year.

Wall Street Analysts Provide Views

In related news, HC Wainwright has recently reaffirmed a “neutral” rating for Xenetic Biosciences’ shares according to a report issued on March 20th.

Institutional Investment in Xenetic Biosciences

There has been some noteworthy activity by institutional investors with respect to Xenetic Biosciences stock. Renaissance Technologies LLC has raised its position in the company by 61.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm now owns 25,550 shares after acquiring an additional 9,700 shares during the quarter, translating to about 1.66% of the company's total shares, valued at approximately $102,000 at the end of the period. In total, institutional investors hold approximately 15.12% of Xenetic Biosciences’ stock.

Overview of Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical entity that focuses on advancing the XCART, a personalized CAR T platform technology designed to specifically target patient-related tumor neoantigens. Currently, the company is working on developing cell-based therapeutics that can target the unique B-cell receptor found on the surface of malignant tumor cells associated with individual patients, particularly for the treatment of B-cell lymphomas.

Short, Interest, Xenetic